Fh535 Suppresses The Growth Of Osteosarcoma In Vitro And Vivo Via Downregulation Wnt/Beta-Catenin Signaling Pathway

Osteosarcoma (OS) is a rare malignancy in the pediatric age group leading causes of cancer-related death. In recent years, increasing studies evaluated the inhibition of the Wnt/beta-catenin pathway as a potential therapeutic approach. Previous studies reported that Wnt/beta-catenin pathway inhibitor FH535 has been shown to suppress tumor progression in various tumors, including lung, prostate and breast cancer. However, there are few studies illustrating the inhibitory effect of FH535 on OS. To test this, we first demonstrated that FH535 inhibits the OS cells (F5M2) proliferation using MTT assay. We then found FH535 decreased invasion and migration ability of F5M2 through transwell assays, and the expression of cyclin D1 and MMP-2 were both down-regulated in FH535 group compared with the control group by western blot. In addition, FH535 suppressed OS growth, reducing the size of OS F5M2 cell xenografts. Together, these results demonstrated that FH535 suppresses the tumor growth of OS in vitro and vivo, suggesting that FH535 may be a promising therapeutic agent for the treatment of OS.